Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1979 1
1981 4
1984 1
1985 3
1987 3
1988 1
1992 1
1995 1
1999 1
2001 1
2002 1
2003 2
2005 3
2007 1
2008 1
2009 1
2010 3
2011 1
2012 1
2013 1
2014 1
2016 2
2017 1
2019 2
2020 3
2021 5
2022 10
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial.
Somaiah N, Conley AP, Parra ER, Lin H, Amini B, Solis Soto L, Salazar R, Barreto C, Chen H, Gite S, Haymaker C, Nassif EF, Bernatchez C, Mitra A, Livingston JA, Ravi V, Araujo DM, Benjamin R, Patel S, Zarzour MA, Sabir S, Lazar AJ, Wang WL, Daw NC, Zhou X, Roland CL, Cooper ZA, Rodriguez-Canales J, Futreal A, Soria JC, Wistuba II, Hwu P. Somaiah N, et al. Among authors: nassif ef. Lancet Oncol. 2022 Sep;23(9):1156-1166. doi: 10.1016/S1470-2045(22)00392-8. Epub 2022 Aug 4. Lancet Oncol. 2022. PMID: 35934010 Clinical Trial.
Myxoid Liposarcomas: Systemic Treatment Options.
Nassif EF, Keung EZ, Thirasastr P, Somaiah N. Nassif EF, et al. Curr Treat Options Oncol. 2023 Apr;24(4):274-291. doi: 10.1007/s11864-023-01057-4. Epub 2023 Feb 28. Curr Treat Options Oncol. 2023. PMID: 36853469 Review.
Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma.
Traweek RS, Cope BM, Roland CL, Keung EZ, Nassif EF, Erstad DJ. Traweek RS, et al. Among authors: nassif ef. Front Oncol. 2022 Nov 10;12:1006959. doi: 10.3389/fonc.2022.1006959. eCollection 2022. Front Oncol. 2022. PMID: 36439412 Free PMC article. Review.
Targeting the Molecular and Immunologic Features of Leiomyosarcoma.
Cope BM, Traweek RS, Lazcano R, Keung EZ, Lazar AJ, Roland CL, Nassif EF. Cope BM, et al. Among authors: nassif ef. Cancers (Basel). 2023 Mar 31;15(7):2099. doi: 10.3390/cancers15072099. Cancers (Basel). 2023. PMID: 37046760 Free PMC article. Review.
The Landscape of Immunotherapy for Retroperitoneal Sarcoma.
Gingrich AA, Nassif EF, Roland CL, Keung EZ. Gingrich AA, et al. Among authors: nassif ef. Curr Oncol. 2023 Feb 9;30(2):2144-2158. doi: 10.3390/curroncol30020165. Curr Oncol. 2023. PMID: 36826126 Free PMC article. Review.
The immune landscape of undifferentiated pleomorphic sarcoma.
Lazcano R, Barreto CM, Salazar R, Carapeto F, Traweek RS, Leung CH, Gite S, Mehta J, Ingram DR, Wani KM, Vu KT, Parra ER, Lu W, Zhou J, Witt RG, Cope B, Thirasastr P, Lin HY, Scally CP, Conley AP, Ratan R, Livingston JA, Zarzour AM, Ludwig J, Araujo D, Ravi V, Patel S, Benjamin R, Wargo J, Wistuba II, Somaiah N, Roland CL, Keung EZ, Solis L, Wang WL, Lazar AJ, Nassif EF. Lazcano R, et al. Among authors: nassif ef. Front Oncol. 2022 Oct 12;12:1008484. doi: 10.3389/fonc.2022.1008484. eCollection 2022. Front Oncol. 2022. PMID: 36313661 Free PMC article.
Sunitinib in kidney cancer: 10 years of experience and development.
Nassif E, Thibault C, Vano Y, Fournier L, Mauge L, Verkarre V, Timsit MO, Mejean A, Tartour E, Oudard S. Nassif E, et al. Expert Rev Anticancer Ther. 2017 Feb;17(2):129-142. doi: 10.1080/14737140.2017.1272415. Epub 2016 Dec 27. Expert Rev Anticancer Ther. 2017. PMID: 27967249 Review.
62 results